Viatris agrees to acquire Pacira for $1.65 billion
On Oct. 8, 2026, Viatris agreed to purchase all outstanding Pacira shares for $36.50 per share in cash, valuing the equity at $1.65 billion. The transaction would add Pacira's EXPAREL and ZILRETTA pain medicines, and Viatris is targeting completion by the end of 2026 after required conditions are met.





